August 24, 2020 -- RNAimmune has secured $2.35 million in seed round financing from multiple venture capital firms to advance its COVID-19 vaccine RV1730 program and neoantigen-based cancer vaccine programs.
Since its establishment as a spinoff of Sirnaomics earlier this year, RNAimmune has deployed its in-house artificial intelligence algorithm for epitope prediction and validation (ALEPVA) for mRNA vaccine and drug design, licensed global exclusive rights for polypeptide-lipid nanoparticle (PLNP) delivery technology, and adopted a large-scale good manufacturing practice manufacturing knowhow from Sirnaomics.
The company is preparing for an investigational new drug filing for RV1730 and is working on advancing its cancer vaccine pipeline.
Copyright © 2020 scienceboard.net